LE WE PMID CA
Liver (Steatohepatosis)2614Leber (Steatohepatose)

Adiponectin

Alcohol

Apolipoprotein B

Choline

Diabetes mellitus (t Incretins)

Endocannabinoid

Eriocitrin

Insulin (resistance)

Interleukin17

Iron (Toxicology)

Kupffer cell

Leptin

Lipoprotein (VLDL)

Lipotoxicity

Liver (Neoplasia HCC)

Liver (Sonography)

Liver (Steatohepatosis)

MAT1A methhionine adenosyltransferase

MAT2A methionine adenosyltransferase

MAT2beta methionine adenosyltransferase

Metabolic syndrome

Metabolism (BASKET)

Metformin

Microsomal triglyceride transfer protein

NK cells

NR1C1 PPAR alpha

Obesity (BASKET)

PGC1alpha

Protein (ptm acetylation)

S Adenosyl methionine

SIRT1

Sirt3

STAT3

Thiazolidinediones

TLR9

TRPV1

UCP2

2008  
1
Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.
[18922966] Pharmacol Rev 60(3): 311-57 (2008)
2008  
2
Causes and metabolic consequences of Fatty liver.
[18723451] Endocr Rev 29(7): 939-60 (2008)
2007  
3
Pathology of nonalcoholic fatty liver disease.
[17951208] Am J Clin Pathol 128(5): 837-47 (2007)
2004  
4
Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.
[15277442] Diabetes Care 27(8): 2057-66 (2004)
2008  
5
The role of the lipogenic pathway in the development of hepatic steatosis.
[19195625] Diabetes Metab 34(6 Pt 2): 643-8 (2008)
2008  
6
Definition and natural history of metabolic steatosis: histology and cellular aspects.
[19195624] Diabetes Metab 34(6 Pt 2): 638-42 (2008)
2004  
7
The ins and outs of mitochondrial dysfunction in NASH.
[15223984] Diabetes Metab 30(2): 121-38 (2004)
2009  
8
Commonly used animal models of non-alcoholic steatohepatitis.
[19502161] Hepatobiliary Pancreat Dis Int 8(3): 233-40 (2009)
2009  
9
Advances in pediatric nonalcoholic fatty liver disease.
[19637286] Hepatology 50(4): 1282-93 (2009)
2009  
10
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
[19065650] Hepatology 49(1): 306-17 (2009)
2008  
11
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.
[18317565] J Clin Invest 118(3): 829-38 (2008)
2007  
12
Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis.
[18198478] J Toxicol Sci 32(5): 453-68 (2007)
2008  
13
Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.
[18442193] World J Gastroenterol 14(16): 2474-86 (2008)
2008  
14
The blind men 'see' the elephant-the many faces of fatty liver disease.
[18240340] World J Gastroenterol 14(6): 831-44 (2008)
2006  
15
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
[17203528] World J Gastroenterol 12(48): 7826-31 (2006)
2006  
16
Treatment of nonalcoholic fatty liver disease.
[16610015] World J Gastroenterol 12(14): 2161-7 (2006)
2006  
17
Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
[16447287] Hepatology 43(2 Suppl 1): S99-S112 (2006)
2005  
18
The histopathology of pediatric nonalcoholic fatty liver disease.
[16116643] Hepatology 42(3): 536-8 (2005)
2006  
19
Fatty liver: imaging patterns and pitfalls.
[17102041] Radiographics 26(6): 1637-53 (2006)
2010  
20
Role of cannabinoids in the development of fatty liver (steatosis).
[20204561] AAPS J 12(2): 233-7 (2010)
2002  
21
Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.
[11804839] Am J Physiol Gastrointest Liver Physiol 282(2): G193-9 (2002)
2002  
22
Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines.
[11751151] Am J Physiol Gastrointest Liver Physiol 282(1): G1-5 (2002)
2008  
23
Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.
[18292184] Am J Physiol Gastrointest Liver Physiol 294(5): G1101-4 (2008)
2009  
24
Noninvasive imaging biomarkers for steatosis assessment.
[19877212] Liver Transpl 15(11): 1389-91 (2009)
2011  
25
Adiponectin, a key adipokine in obesity related liver diseases.
[21734787] World J Gastroenterol 17(23): 2801-11 (2011)
2011  
26
Betaine and nonalcoholic steatohepatitis: back to the future?
[21990946] World J Gastroenterol 17(32): 3663-4 (2011)
2011  
27
JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease.
[21987620] World J Gastroenterol 17(33): 3785-94 (2011)
2011  
28
Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis.
[22039318] World J Gastroenterol 17(36): 4055-62 (2011)
2010  
29
Roles of liver innate immune cells in nonalcoholic fatty liver disease.
[20872965] World J Gastroenterol 16(37): 4652-60 (2010)
2010  
30
Histopathology of nonalcoholic fatty liver disease.
[21072891] World J Gastroenterol 16(42): 5286-96 (2010)
2010  
31
Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease.
[20458758] World J Gastroenterol 16(18): 2223-6 (2010)
2007  
32
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.
[17659704] World J Gastroenterol 13(26): 3540-53 (2007)
2011  
33
Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis.
[21350309] J Pharmacol Sci 115(3): 270-3 (2011)
2004  
34
Molecular mediators of hepatic steatosis and liver injury.
[15254578] J Clin Invest 114(2): 147-52 (2004)
2011  
35
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
[22059955] Health Technol Assess 15(38): 1-110 (2011)
2007  
36
Pathology of fatty liver disease.
[17486051] Mod Pathol 20 Suppl 1(-): S40-8 (2007)
2010  
37
Inflammatory mediators of hepatic steatosis.
[20300479] Mediators Inflamm 2010(-): 837419 (2010)
2004  
38
Non-alcoholic statohepatitis: physiopathological, clinical and therapeutic implications.
[15506907] Rev Esp Enferm Dig 96(9): 628-39; 440-8 (2004)
2011  
39
Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation.
[21044047] Biochem J 433(3): 505-14 (2011)
2009  
40
Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.
[19356714] Cell Metab 9(4): 327-38 (2009)
2012  
41
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
[22134222] Curr Opin Gastroenterol 28(2): 159-65 (2012)
2008  
42
Hepatic microcirculation in fatty liver disease.
[18484615] Anat Rec (Hoboken) 291(6): 684-92 (2008)
2010  
43
Nonalcoholic steatohepatitis: a review of the literature and updates in management.
[20710138] South Med J 103(6): 547-50 (2010)
2010  
44
Pathogenesis of non-alcoholic fatty liver disease.
[19914930] QJM 103(2): 71-83 (2010)
2003  
45
Non-alcoholic fatty liver: a common manifestation of a metabolic disorder.
[14500857] QJM 96(10): 699-709 (2003)
2004  
46
Nonalcoholic steatohepatitis.
[15554595] Neth J Med 62(7): 217-24 (2004)
2008  
47
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
[18939388] Cleve Clin J Med 75(10): 721-8 (2008)
2007  
48
Managing nonalcoholic fatty liver disease: recommendations for family physicians.
[17872748] Can Fam Physician 53(5): 857-63 (2007)
2007  
49
The genetics of nonalcoholic fatty liver disease.
[17519829] Ann Hepatol 6(2): 83-8 (2007)
2004  
50
Nonalcoholic fatty liver disease.
[15505593] Ann Hepatol 3(3): 93-9 (2004)
2009  
51
Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
[19753129] Mediators Inflamm 2009(-): 831670 (2009)
2007  
52
GI epidemiology: nonalcoholic fatty liver disease.
[17402991] Aliment Pharmacol Ther 25(8): 883-9 (2007)
2006  
53
Review article: Drug therapy for non-alcoholic fatty liver disease.
[16393299] Aliment Pharmacol Ther 23(2): 207-15 (2006)
2005  
54
Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones.
[16268963] Aliment Pharmacol Ther 22(10): 897-905 (2005)
2003  
55
Review article: Non-alcoholic fatty liver disease.
[12694079] Aliment Pharmacol Ther 17(8): 977-86 (2003)
2010  
56
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.
[20415840] Aliment Pharmacol Ther 31(7): 679-92 (2010)
2008  
57
Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
[18532991] Aliment Pharmacol Ther 28(5): 503-22 (2008)
2008  
58
Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[18410557] Aliment Pharmacol Ther 28(1): 2-12 (2008)
2008  
59
Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.
[18397387] Aliment Pharmacol Ther 28(1): 13-24 (2008)
2007  
60
Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery.
[18081662] Aliment Pharmacol Ther 26 Suppl 2(-): 195-201 (2007)
2006  
61
Treatment of non-alcoholic fatty liver disease.
[16679470] Postgrad Med J 82(967): 315-22 (2006)
2008  
62
2005  
63
Nonalcoholic fatty liver disease.
[15795412] CMAJ 172(7): 899-905 (2005)
2011  
64
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[21198708] Aliment Pharmacol Ther 33(5): 525-40 (2011)
2009  
65
Nonalcoholic fatty liver disease.
[19074370] J Lipid Res 50 Suppl(-): S412-6 (2009)
2008  
66
2007  
67
A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.
[17483247] J Clin Pathol 60(12): 1384-91 (2007)
2012  
68
TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice.
[22395410] Pflugers Arch 463(5): 727-32 (2012)
2010  
69
Innate immunity and steatohepatitis: a critical role of another toll (TLR-9).
[20639084] Gastroenterology 139(1): 27-30 (2010)
2008  
70
Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells.
[18166364] Gastroenterology 134(1): 351-3 (2008)
2011  
71
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
[21765869] Therap Adv Gastroenterol 4(4): 249-63 (2011)
2011  
72
Glitazones for human nonalcoholic steatohepatitis.
[21922031] Therap Adv Gastroenterol 4(5): 325-34 (2011)
2011  
73
Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress.
[21150132] Drug Metab Pharmacokinet 26(1): 30-46 (2011)
2009  
74
The metabolic syndrome and nonalcoholic fatty liver disease in children.
[19444112] Curr Opin Pediatr 21(4): 529-35 (2009)
2011  
75
Ultrastructural findings in human nonalcoholic steatohepatitis.
[21476907] Expert Rev Gastroenterol Hepatol 5(2): 141-5 (2011)
2011  
76
The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate?
[21810223] Ital J Pediatr 37(-): 36 (2011)
2008  
77
Nonalcoholic fatty liver disease in children.
[19155426] J Am Coll Nutr 27(6): 667-76 (2008)
2009  
78
Kupffer cells in non-alcoholic fatty liver disease: the emerging view.
[19447517] J Hepatol 51(1): 212-23 (2009)
2008  
79
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease.
[18956292] Semin Liver Dis 28(4): 360-9 (2008)
2010  
80
Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children.
[20808243] J Pediatr Gastroenterol Nutr 51(4): 378-9 (2010)
2008  
81
S-Adenosylmethionine in cell growth, apoptosis and liver cancer.
[18336669] J Gastroenterol Hepatol 23 Suppl 1(-): S73-7 (2008)
2009  
82
NASH: The Hepatic injury of Metabolic syndrome: a brief update.
[21475547] Int J Health Sci (Qassim) 3(2): 265-70 (2009)
2008  
83
Risk factors and mechanisms of non-alcoholic steatohepatitis.
[18667295] Pathophysiology 15(2): 109-14 (2008)
2011  
84
Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target.
[21552420] Int J Biol Sci 7(5): 536-50 (2011)
2010  
85
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).
[20426802] Lipids Health Dis 9(-): 42 (2010)
2011  
86
Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease.
[21328622] Biofactors 37(1): 8-16 (2011)
2010  
87
An overview of nonalcoholic steatohepatitis: past, present and future directions.
[21188334] J Gastrointestin Liver Dis 19(4): 415-23 (2010)
PMC   
88
Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism.
[24396389] Clin Dev Immunol 2013():253046 (2013)
PMC   
89
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.
[24459637] Clin Mol Hepatol 19(4):325-48 (2013)
PMC   
90
Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes.
[24375162] Iran Biomed J 18(1):41-8 (2014)
PMC   
91
Caveolin-1 provides palliation for adverse hepatic reactions in hypercholesterolemic rabbits.
[24475013] PLoS One 9(1):e71862 (2014)
PMC   
92
Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.
[24424211] Sci Rep 4():3708 (2014)
PMC   
93
Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease.
[24505350] PLoS One 9(2):e88005 (2014)
PMC   
94
Clinical approaches to non-alcoholic fatty liver disease.
[24587650] World J Gastroenterol 20(7):1712-23 (2014)
PMC   
95
5-cholesten-3beta,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.
[23258548] Mol Pharmacol 83(3):648-58 (2013)
PMC   
96
Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.
[23560695] J Diabetes 5(4):406-15 (2013)
PMC   
97
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
[24648894] Biomed Rep 1(1):57-64 (2013)
PMC   
98
Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis.
[24660114] Med Chem (Los Angeles) 2(): (2012)
PMC   
99
PMC   
100
A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.
[24659891] World J Gastroenterol 20(11):3002-10 (2014)
PMC   
101
Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat).
[24651520] PLoS One 9(3):e92656 (2014)
PMC   
102
Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score.
[24672667] Gut Liver 8(2):228 (2014)
PMC   
103
Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.
[24683373] Gastroenterol Hepatol (N Y) 8(10):661-8 (2012)
PMC   
104
Thyroid hormone analogues and derivatives: Actions in fatty liver.
[24672641] World J Hepatol 6(3):114-29 (2014)
PMC   
105
Pathophysiology of NASH: perspectives for a targeted treatment.
[23394092] Curr Pharm Des 19(29):5250-69 (2013)
PMC   
106
Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis.
[23292069] FASEB J 27(4):1674-89 (2013)
PMC   
107
Therapies for nonalcoholic steatohepatitis.
[24707234] Gastroenterol Hepatol (N Y) 9(1):40-2 (2013)
PMC   
108
Predictors of nonalcoholic steatohepatitis in obese children.
[22129796] Gastroenterol Nurs 34(6):434-7 (2011)
PMC   
109
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
[23175136] Hepatology 57(4):1357-65 (2013)
PMC   
110
The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro.
[24603540] Int J Mol Sci 15(3):4019-30 (2014)
PMC   
111
Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.
[23207144] J Hepatol 58(4):778-84 (2013)
PMC   
112
Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.
[24764670] World J Gastroenterol 20(15):4335-40 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia